Cancer stem-cell start up OncoMed has raised $93 million in a second round financing extension, bringing its total to around $154 million. The company, which has raised $204 million to date, plans to use the funds for its cancer stem-cell antibody programs, including its lead compound and a second antibody, through Phase 2 clinical trials.
London-based Nomura Phase4 Ventures Limited led the inside round extension, joined by previous investors US Venture Partners, Bay Partners, Morgenthaler Ventures, Latterell Venture Partners, The Vertical Group, Adams Street Partners, and DeNovo Ventures.
OncoMed also reports that it has established a strategic partnership with GlaxoSmithKline which the company claims could be worth as much as $1.4 billion.
To learn more about OncoMed:
- read this San Jose Business Journal story
- check out OncoMed's website